Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed EBITDA Margin for 9 consecutive years, with 22.67% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 5.0% year-over-year to 22.67%, compared with a TTM value of 16.33% through Dec 2025, up 290.0%, and an annual FY2025 reading of 16.33%, up 290.0% over the prior year.
  • EBITDA Margin was 22.67% for Q4 2025 at Puma Biotechnology, up from 17.57% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 27.41% in Q3 2024 and bottomed at 31.16% in Q2 2021.
  • Average EBITDA Margin over 5 years is 8.56%, with a median of 11.79% recorded in 2022.
  • The sharpest move saw EBITDA Margin plummeted -4126bps in 2021, then surged 5142bps in 2022.
  • Year by year, EBITDA Margin stood at 12.16% in 2021, then dropped by -6bps to 11.43% in 2022, then skyrocketed by 79bps to 20.5% in 2023, then rose by 10bps to 22.62% in 2024, then rose by 0bps to 22.67% in 2025.
  • Business Quant data shows EBITDA Margin for PBYI at 22.67% in Q4 2025, 17.57% in Q3 2025, and 12.66% in Q2 2025.